You are here

Generic Version of Oral Contraceptive Seasonale Launched

WOODCLIFF LAKE, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE:BRL) today announced that its subsidiary Barr Laboratories, Inc. is launching a generic version of the Company's proprietary SEASONALE(R) extended-cycle oral contraceptive under the tradename Jolessa(TM). The Company launched its generic version of SEASONALE following the final U.S. Food and Drug Administration (FDA) approval of Watson Laboratories, Inc.'s Abbreviated New Drug Application (ANDA) for SEASONALE. Watson received approval following the expiration of the Company's 3-year New Product Exclusivity on September 5, 2006.

"While issues related to our application with the Patent and Trademark Office to reissue the patent covering SEASONALE are being resolved, we will take those steps appropriate to defend our interests in this proprietary product," said Bruce L. Downey, Barr's Chairman and CEO. "It is our obligation to preserve our rightful interests in this product, as well as continue the promotion of our SEASONIQUE(TM) extended-cycle oral contraceptive, which represents the next generation in a category we created with the approval and launch of SEASONALE."

In May 2006, Barr received approval for its SEASONIQUE (levonorgestrel/ethinyl estradiol tablets 0.15 mg/0.03 mg and ethinyl estradiol tablets 0.01 mg) extended-cycle oral contraceptive for the prevention of pregnancy. SEASONIQUE represents the next generation of extended-cycle oral contraceptives in a category the Company created with the launch of the SEASONALE extended-cycle oral contraceptive in 2003. SEASONIQUE was shipped to trade customers and was available by prescription to women in July 2006. The Company initiated full scale detailing for SEASONIQUE to healthcare providers in August using its Duramed Sales Forces. The Company immediately initiated multiple marketing programs aimed at healthcare providers and patients. Information about SEASONIQUE is available at

In June 2004 the Company announced that it received notification that Watson Laboratories, Inc. had filed an ANDA containing a paragraph IV certification asserting that the patent covering SEASONALE is invalid, unenforceable or would not be infringed by Watson's generic product. Barr did not initiate patent infringement litigation with respect to Watson's ANDA. In July 2004, Barr filed an application seeking reissue of the '032 patent with the Patent and Trademark Office (PTO) in July 2004. In May 2006, the Company received a Non-Final Rejection notice from the PTO and in July 2006 responded to the issues raised by the PTO in its Non-Final Rejection. The PTO continues to evaluate the Company's application for reissuance and in the meanwhile the '032 patent remains in effect and continues to be listed in the FDA's Orange Book.

Source: Barr Pharmaceuticals

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation